Edition:
United States

Bio Rad Laboratories Inc (BIO)

BIO on New York Consolidated

258.69USD
22 Nov 2017
Change (% chg)

$3.01 (+1.18%)
Prev Close
$255.68
Open
$255.91
Day's High
$258.95
Day's Low
$253.90
Volume
119,776
Avg. Vol
176,767
52-wk High
$268.40
52-wk Low
$169.18

Latest Key Developments (Source: Significant Developments)

Bio Rad Laboratories reports Q3 earnings per share $0.91
Thursday, 2 Nov 2017 04:15pm EDT 

Nov 2 (Reuters) - Bio Rad Laboratories Inc :Bio Rad Laboratories Inc reports third-quarter 2017 financial results.Q3 earnings per share $0.91.Q3 sales $535 million versus I/B/E/S view $508 million.Sees q4 2017 sales $615 million to $625 million.Q3 earnings per share view $0.38 -- Thomson Reuters I/B/E/S.  Full Article

Bio-Rad reports Q2 earnings per share $0.17
Thursday, 3 Aug 2017 04:42pm EDT 

Aug 3 (Reuters) - Bio Rad Laboratories Inc -:Bio-Rad reports second-quarter 2017 financial results.Q2 earnings per share $0.17.Q2 sales $504.7 million versus i/b/e/s view $515.8 million.Q2 earnings per share view $0.56 -- Thomson Reuters I/B/E/S.Bio Rad Laboratories Inc - for full year 2017, company continues to anticipate currency-neutral organic sales growth of approximately 4 percent,.Bio Rad Laboratories - lowering estimate for currency-neutral operating profit for fy2017 from 7 percent of sales to now be in 6 to 6.5 percent range​.Bio Rad Laboratories Inc - ‍addition of recently acquired raindance technologies could add up to another 1 percent of growth in sales for FY 2017​.  Full Article

Bio Rad Laboratories receives FDA clearance for Bioplex 2200 syphilis total & RPR assay​
Monday, 12 Jun 2017 08:30am EDT 

June 12 (Reuters) - Bio Rad Laboratories Inc ::Bio Rad Laboratories Inc - ‍has received U.S. Food and Drug Administration clearance for its Bioplex 2200 syphilis total & RPR assay​.  Full Article

Bio-Rad Laboratories reports Q1 earnings per share $0.41
Thursday, 4 May 2017 04:15pm EDT 

May 4 (Reuters) - Bio-Rad Laboratories Inc :Bio-Rad reports first-quarter 2017 financial results.Q1 earnings per share $0.41.Q1 revenue $500.1 million versus I/B/E/S view $477.8 million.Q1 earnings per share view $0.30 -- Thomson Reuters I/B/E/S.Bio-Rad Laboratories Inc - for full year 2017, company continues to anticipate currency neutral revenue growth of approximately 4 percent.  Full Article

Bio Rad Laboratories Inc says expects to achieve long-term currency-neutral revenue growth of approximately 3% to 5%
Monday, 13 Mar 2017 08:31am EDT 

Bio Rad Laboratories Inc : Bio Rad Laboratories Inc says expects to achieve long-term currency-neutral revenue growth of approximately 3% to 5% . Bio Rad Laboratories Inc says expects to achieve currency-neutral EBITDA margin of greater than 20% by 2020 . Bio Rad Laboratories Inc says reiterated its 2017 financial outlook .FY2017 earnings per share view $2.80, revenue view $2.11 billion -- Thomson Reuters I/B/E/S.  Full Article

Bio Rad Laboratories reports Q2 profit $0.61 per share
Wednesday, 3 Aug 2016 04:15pm EDT 

Bio Rad Laboratories Inc : Second-Quarter reported revenues were $516.8 million, an increase of 2.1 percent . Bio-Rad reports second-quarter 2016 financial results .Net income for Q2 of 2016 was $18.0 million, or $0.61 per share.  Full Article

Bio-Rad Laboratories Inc's TANGO infinity Receives FDA 510(k) Clearance for U.S. Markets
Monday, 21 Dec 2015 04:21pm EST 

Bio-Rad Laboratories:Received U.S. Food and Drug Administration clearance to market its TANGO infinity system in the U.S.The system automates routine blood typing and screening testing procedures for patients and donors.  Full Article

BRIEF-Bio Rad Laboratories reports Q3 earnings per share $0.91

* Bio Rad Laboratories Inc reports third-quarter 2017 financial results